Company intelligence / Profile preview

KDAc Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

KDAc Therapeutics developed highly selective, isoform-specific histone deacetylase inhibitors. Its lead asset, KDAc-0001 (OKI-422), targets cancers with specific genetic backgrounds (notably HAT loss-of-function), acting in synergy with checkpoint inhibitors. Preclinical studies suggest promising epigenetic reactivation and anti-tumor effects; further clinical development is led by OnKure under license.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

OnKure (exclusive license/option agreement for lead candidate)Broad Institute of MIT and Harvard (licensing of foundational IP)

Beyond the preview

Go deeper on KDAc Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDAc Therapeutics.

Explore the full profile